Core Laboratories (CLB) Stock Forecast, Price Target & Predictions
CLB Stock Forecast
Core Laboratories stock forecast is as follows: an average price target of $25.00 (represents a 18.37% upside from CLB’s last price of $21.12) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
CLB Price Target
The average price target for Core Laboratories (CLB) is $25.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $17.00. This represents a potential 18.37% upside from CLB's last price of $21.12.
CLB Analyst Ratings
According to 4 Wall Street analysts, Core Laboratories's rating consensus is 'Hold'. The analyst rating breakdown for CLB stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (75.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Core Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 15, 2024 | Luke Lemoine | Piper Sandler | - | - | -21.95% | -19.51% |
| Feb 07, 2023 | Citigroup | - | - | -0.78% | 23.11% | |
| May 02, 2022 | Morgan Stanley | - | - | 20.10% | 51.52% |
The latest Core Laboratories stock forecast, released on Jul 15, 2024 by Luke Lemoine from Piper Sandler, set a price target of $17.00, which represents a -21.95% decrease from the stock price at the time of the forecast ($21.78), and a -19.51% decrease from CLB last price ($21.12).
Core Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $17.00 |
| Last Closing Price | $21.12 | $21.12 | $21.12 |
| Upside/Downside | -100.00% | -100.00% | -19.51% |
In the current month, the average price target of Core Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Core Laboratories's last price of $21.12. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 15, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Feb 07, 2023 | Citigroup | Neutral | Neutral | Hold |
| Jan 09, 2023 | Bank of America Securities | Neutral | Upgrade | |
| Oct 06, 2022 | Citigroup | Neutral | Upgrade | |
| Sep 26, 2022 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| May 02, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Core Laboratories's last stock rating was published by Piper Sandler on Jul 15, 2024. The company gave CLB a "Neutral" rating, the same as its previous rate.
Core Laboratories Financial Forecast
Core Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $128.36M | $127.57M | $125.97M | $120.90M | $115.30M | $125.14M | $117.98M | $118.75M | $108.38M | $113.75M | $105.38M | $115.74M | $152.40M | $156.78M | $173.20M |
| Avg Forecast | $140.90M | $140.88M | $139.95M | $137.03M | $139.30M | $138.70M | $134.56M | $130.71M | $132.55M | $134.16M | $132.85M | $124.13M | $128.00M | $129.81M | $131.25M | $126.18M | $130.03M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| High Forecast | $143.62M | $143.60M | $142.65M | $139.67M | $141.98M | $141.37M | $137.16M | $131.65M | $135.10M | $134.73M | $132.85M | $124.13M | $129.20M | $134.33M | $133.78M | $128.62M | $132.53M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| Low Forecast | $138.86M | $138.84M | $137.93M | $135.05M | $137.28M | $136.69M | $132.61M | $129.76M | $130.63M | $133.58M | $132.85M | $124.13M | $126.59M | $128.39M | $129.35M | $124.36M | $128.14M | $126.08M | $121.46M | $113.01M | $122.42M | $122.68M | $119.53M | $110.51M | $109.19M | $109.76M | $115.91M | $152.37M | $155.95M | $171.64M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.98% | 1.00% | 1.00% | 1.02% | 1.02% | 0.96% | 0.99% | 0.98% | 1.04% | 0.96% | 1.00% | 1.00% | 1.01% | 1.01% |
Core Laboratories's average Quarter revenue forecast for Jun 23 based on 3 analysts is $131.25M, with a low forecast of $129.35M, and a high forecast of $133.78M. CLB's average Quarter revenue forecast represents a 2.25% increase compared to the company's last Quarter revenue of $128.36M (Mar 23).
Core Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.53M | $19.69M | $18.82M | $16.01M | $4.17M | $18.50M | $11.00M | $17.39M | $16.39M | $27.83M | $16.46M | $2.82M | $-103.61M | $26.63M | $36.42M |
| Avg Forecast | $12.85M | $12.85M | $12.77M | $12.50M | $12.71M | $12.65M | $12.28M | $11.92M | $12.09M | $12.24M | $12.12M | $5.54M | $11.68M | $11.84M | $11.97M | $5.03M | $20.35M | $18.35M | $17.68M | $4.57M | $17.82M | $17.86M | $17.40M | $13.87M | $15.89M | $15.97M | $16.87M | $-112.76M | $22.70M | $24.98M |
| High Forecast | $13.10M | $13.10M | $13.01M | $12.74M | $12.95M | $12.90M | $12.51M | $12.01M | $12.33M | $12.29M | $12.12M | $6.64M | $11.79M | $12.26M | $12.20M | $6.04M | $24.42M | $18.35M | $17.68M | $5.49M | $17.82M | $17.86M | $17.40M | $16.64M | $15.89M | $15.97M | $16.87M | $-90.21M | $22.70M | $24.98M |
| Low Forecast | $12.67M | $12.67M | $12.58M | $12.32M | $12.52M | $12.47M | $12.10M | $11.84M | $11.92M | $12.19M | $12.12M | $4.43M | $11.55M | $11.71M | $11.80M | $4.03M | $16.28M | $18.35M | $17.68M | $3.66M | $17.82M | $17.86M | $17.40M | $11.10M | $15.89M | $15.97M | $16.87M | $-135.31M | $22.70M | $24.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09% | 0.97% | 1.03% | 0.91% | 0.91% | 1.04% | 0.62% | 1.00% | 1.18% | 1.75% | 1.03% | 0.17% | 0.92% | 1.17% | 1.46% |
3 analysts predict CLB's average Quarter EBITDA for Jun 23 to be $11.97M, with a high of $12.20M and a low of $11.80M. This is 13.77% upper than Core Laboratories's previous annual EBITDA (Mar 23) of $10.53M.
Core Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.37M | $6.75M | $7.52M | $7.07M | $-1.84M | $2.79M | $874.00K | $8.06M | $8.11M | $13.54M | $2.96M | $-5.72M | $-108.42M | $10.33M | $23.73M |
| Avg Forecast | $15.36M | $15.04M | $14.54M | $13.54M | $13.61M | $13.27M | $12.13M | $10.83M | $10.83M | $11.67M | $9.36M | $-2.54M | $8.99M | $10.50M | $9.75M | $-2.31M | $2.96M | $7.27M | $6.54M | $-2.10M | $9.60M | $8.91M | $9.12M | $6.86M | $7.32M | $6.90M | $5.22M | $-117.99M | $17.76M | $23.24M |
| High Forecast | $15.75M | $15.41M | $14.91M | $13.88M | $13.95M | $13.61M | $12.43M | $11.11M | $11.69M | $11.83M | $9.37M | $-2.03M | $9.22M | $11.45M | $10.00M | $-1.85M | $3.55M | $7.27M | $6.54M | $-1.68M | $9.60M | $8.91M | $9.12M | $8.23M | $7.32M | $6.90M | $5.22M | $-94.39M | $17.76M | $23.24M |
| Low Forecast | $15.07M | $14.75M | $14.27M | $13.29M | $13.36M | $13.02M | $11.90M | $10.63M | $9.96M | $11.50M | $9.36M | $-3.05M | $8.09M | $8.59M | $9.57M | $-2.77M | $2.37M | $7.27M | $6.54M | $-2.52M | $9.60M | $8.91M | $9.12M | $5.49M | $7.32M | $6.90M | $5.22M | $-141.59M | $17.76M | $23.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.03% | 2.28% | 1.03% | 1.08% | 0.88% | 0.29% | 0.10% | 0.88% | 1.18% | 1.85% | 0.43% | -1.10% | 0.92% | 0.58% | 1.02% |
Core Laboratories's average Quarter net income forecast for Jun 23 is $9.75M, with a range of $9.57M to $10.00M. CLB's average Quarter net income forecast represents a 310.93% increase compared to the company's last Quarter net income of $2.37M (Mar 23).
Core Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.33M | $8.72M | $10.00M | $6.85M | $12.54M | $10.93M | $15.12M | $9.67M | $8.46M | $-3.69M | $8.94M | $9.22M | $19.57M | $9.77M | $11.01M |
| Avg Forecast | $11.06M | $11.06M | $10.99M | $10.76M | $10.93M | $10.89M | $10.56M | $10.26M | $10.40M | $10.53M | $10.43M | $16.87M | $10.05M | $10.19M | $10.30M | $15.33M | $12.02M | $9.90M | $9.53M | $13.94M | $9.61M | $9.63M | $9.38M | $7.16M | $8.57M | $8.61M | $9.10M | $21.29M | $12.24M | $13.47M |
| High Forecast | $11.27M | $11.27M | $11.20M | $10.96M | $11.14M | $11.10M | $10.77M | $10.33M | $10.60M | $10.58M | $10.43M | $20.24M | $10.14M | $10.54M | $10.50M | $18.40M | $14.42M | $9.90M | $9.53M | $16.73M | $9.61M | $9.63M | $9.38M | $8.59M | $8.57M | $8.61M | $9.10M | $25.55M | $12.24M | $13.47M |
| Low Forecast | $10.90M | $10.90M | $10.83M | $10.60M | $10.78M | $10.73M | $10.41M | $10.18M | $10.25M | $10.48M | $10.43M | $13.49M | $9.94M | $10.08M | $10.15M | $12.27M | $9.62M | $9.90M | $9.53M | $11.15M | $9.61M | $9.63M | $9.38M | $5.73M | $8.57M | $8.61M | $9.10M | $17.03M | $12.24M | $13.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.73% | 1.01% | 0.72% | 0.90% | 1.14% | 1.57% | 1.03% | 1.18% | -0.43% | 1.04% | 1.01% | 0.92% | 0.80% | 0.82% |
Core Laboratories's average Quarter SG&A projection for Jun 23 is $10.30M, based on 3 Wall Street analysts, with a range of $10.15M to $10.50M. The forecast indicates a -36.92% fall compared to CLB last annual SG&A of $16.33M (Mar 23).
Core Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $0.14 | $0.16 | $0.15 | $-0.04 | $0.06 | $0.02 | $0.17 | $0.18 | $0.30 | $0.07 | $-0.13 | $-2.44 | $0.23 | $0.53 |
| Avg Forecast | $0.32 | $0.31 | $0.30 | $0.28 | $0.28 | $0.28 | $0.25 | $0.23 | $0.23 | $0.24 | $0.20 | $0.16 | $0.19 | $0.22 | $0.20 | $0.16 | $0.19 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| High Forecast | $0.33 | $0.32 | $0.31 | $0.29 | $0.29 | $0.28 | $0.26 | $0.23 | $0.24 | $0.25 | $0.20 | $0.16 | $0.19 | $0.24 | $0.21 | $0.16 | $0.20 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| Low Forecast | $0.32 | $0.31 | $0.30 | $0.28 | $0.28 | $0.27 | $0.25 | $0.22 | $0.21 | $0.24 | $0.20 | $0.16 | $0.17 | $0.18 | $0.20 | $0.16 | $0.19 | $0.15 | $0.14 | $0.07 | $0.20 | $0.19 | $0.19 | $0.13 | $0.15 | $0.14 | $0.11 | $0.32 | $0.37 | $0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32% | 0.72% | 1.05% | 1.10% | -0.60% | 0.30% | 0.10% | 0.91% | 1.34% | 1.98% | 0.46% | -1.18% | -7.58% | 0.62% | 1.10% |
According to 3 Wall Street analysts, Core Laboratories's projected average Quarter EPS for Jun 23 is $0.20, with a low estimate of $0.20 and a high estimate of $0.21. This represents a 300.63% increase compared to CLB previous annual EPS of $0.05 (Mar 23).
Core Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RES | RPC | - | - | 62.60% | Hold |
| NR | Newpark Resources | - | - | 41.57% | Buy |
| OIS | Oil States | - | - | 37.87% | Hold |
| NEX | NexTier Oilfield Solutions | - | - | 27.24% | Hold |
| NOV | NOV | - | - | 26.04% | Buy |
| CHX | ChampionX | - | - | 22.54% | Buy |
| DNOW | NOW | - | - | 22.37% | |
| CLB | Core Laboratories | - | - | 18.37% | Hold |
| MRC | MRC Global | - | - | 14.37% | Buy |
| NGS | Natural Gas Services Group | - | - | 2.83% | Buy |
| WHD | Cactus | - | - | -21.11% | Hold |
| OII | Oceaneering | - | - | -27.11% | Buy |